Announcements Trials
Browse Landscape

Status

Recruiting 2Completed 2Terminated 1Enrolling by invitation 1Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

Educational Status 5Interviews as Topic 4Methods 3Magnetic Resonance Imaging 3Early Intervention, Educational 3Cisplatin 3Blood Specimen Collection 3pembrolizumab 2Standard of Care 2Nivolumab 2Music Therapy 2Gemcitabine 2Counseling 2zilucoplan 1tislelizumab 1somapacitan 1sacituzumab govitecan 1rozanolixizumab 1oxycodone-acetaminophen 1ibrutinib 1futibatinib 1fluorodopa F 18 1erdafitinib 1enzalutamide 1enfortumab vedotin 1dynorphin-converting endopeptidase 1durvalumab 1dalpiciclib 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × brexucabtagene autoleucel × 90 days × Clear all
NCT05041309 2026-05-14

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Gilead Sciences

Enrolling by invitation
1,000 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡